Carl Zeiss Meditec Ag (CZMWF) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Carl Zeiss Meditech AG Analyst Conference 9M 2023-2024 results. At this time, all participants have been placed on listen-only mode. The floor will be open for questions following the presentation. Let me now turn the floor over to your hosts, Christian Frerich, Head of Investor. Hey, everybody. Welcome to our in-list call. With me, as usual, is our management, our president, CEO, Markus Weber, and our CFO, Justus Wehmer. They will guide you through our financials with some prepared remarks, and afterwards, we look forward to take your questions. I would like to hand over to Markus. Yeah, thank you so much, Sebastian, and also a warm good morning and welcome from my side, ladies and gentlemen. Welcome to the nine-month 23-24 Analyst Conference of Carl Zeiss Meditech AG. So let's have first a brief look at our agenda. I will start off with an overview, as usual, of the results and just to give more insight into the financials. Following that, we would like to provide deeper insights into what we are doing about cost control measures and some details around recent order development. Finally, we'll update you on the outlook for the remainder of the fiscal year, 2023-2024. And afterwards, as usual, we will be very open for your questions. We discussed the business situation of the first eight months. In mid-June, the third quarter results reflect what we shared with you when we lowered revenues. Revenue and profit are both under continued pressure year-on-year. The respective investment climate and equity markets, as well as weaker consumer sentiment in our effective business, continue to create headwinds for our business. It's the first time that DORC was consolidated in the Q3 numbers. Please note the reported numb...